Results 171 to 180 of about 182,114 (282)

Improving detection of candidates for botulinum toxin therapy in spasticity: an interprofessional screening approach. [PDF]

Front Neurol
Rudelstorfer M, Mayr-Pirker B, Trinka E, Iglseder B, Radlberger RF.   +4 more
europepmc   +1 more source

Emotional Improvement Despite General Clinical Deterioration During Multidisciplinary Rehabilitation in Stiff Person Syndrome: A Longitudinal Case Report

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT We report a woman with anti‐GAD‐positive Stiff Person Syndrome undergoing two multidisciplinary neurorehabilitation admissions. A Transactional Analysis‐informed neuropsychotherapeutic intervention supported emotional adaptation and goal transition from recovery to adaptation.
Marianna Contrada, Federica Scarfone, Martina Vatrano, Isabel Mantia, Natascia De Cicco, Maria Girolama Raso, Antonio Cerasa, Maria Elena Pugliese, Valentina Errigo, Riccardo Spanò   +9 more
wiley   +1 more source

Botulinum toxin A for the Treatment of Androgenetic Alopecia: A Review. [PDF]

Cureus
Basch L, Carver C, Jacobs R.
europepmc   +1 more source

Report of Adverse Events Associated With Cutaneous Procedures: Update From the CAPER Registry

Lasers in Surgery and Medicine, Volume 58, Issue 9, Page 796-801, November 2026.
ABSTRACT Objectives To systematically evaluate submissions to the CAPER database by analyzing procedural context, characteristics of reported adverse events (AEs), and provider involvement in order to identify patterns with potential implications for patient safety.
Sabrina S. Smith, Michael D. Yi, Elizabeth Zhang, Joycie Chang, Thanvi Gullapalli, Doroteja Dragovic, Vanessa J. Lazaro‐Camp, Ashish C. Bhatia, Arisa Ortiz, Murad Alam   +9 more
wiley   +1 more source

On the Study of Botulinum Toxin A Actions: Beyond the Neuromodulation Induced by SNAP-25 Cleavage. [PDF]

Toxins (Basel)
Rasetti-Escargueil C, Palea S.
europepmc   +1 more source

Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect

, 2019
Bagus Komang SatriyasaDepartment of Pharmacology, Faculty of Medicine, Udayana University, Bali, IndonesiaBackground: Botulinum toxin (Botox) consists of 7 types of neurotoxins; however, only toxins A and B are used clinically.
Satriyasa BK
core  

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1476-1478, November 2026.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Save the Bladder: Continent Urinary Diversion as Best Practice for Patients With Refractory Neurogenic Lower Urinary Tract Dysfunction

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1482-1486, November 2026.
ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley   +1 more source

Early Treatment of Post-Stroke Spasticity with Botulinum Toxin Type A: Myth or Reality? [PDF]

Toxins (Basel)
Picelli A, Di Censo R, Smania N, Varalta V, Filippetti M.   +4 more
europepmc   +1 more source

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source